The strides made in 2023, such as Merck's animal use phase-out and partnerships like Astellas and MIMETAS', alongside the FDA Modernization Act 2.0, set an exciting precedent. Despite this, oncology therapeutics face a 20% translation rate into the clinic, highlighting the need for better preclinical tools. The 8th Annual Tumor Models San Francisco Summit, running from 09:00 to 17:00, promises 25+ case studies empowering candidate selection workflows. Insights from Amgen, IGM Biosciences, Rondo Therapeutics, and others on model selection criteria, genetically engineered models' potential from Revolution Medicines, PDX models for ADC studies with Sutro Biopharma, and tumor models in cell therapy by Arsenal Biosciences will be shared. Takeda will delve into tumor microenvironment complexities using spatial biology and digital pathology tools. Join us for accelerated, cost-effective clinical translatability enhancement! 

[Read on tumor-models-sf.com](https://tumor-models-sf.com/)

Continue reading at tumor-models-sf.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share